GleamWall
中文EN

TPST Tempest Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1544227 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.6%
TTM EPS YoY67.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,797.6%
ROA-313.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets120.9%
Debt / equity—
Current ratio0.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$207,000$1.82M$114,000$539,000$570,000$3.87M$7.63M$10.74M
SG&A expense$2.62M$3.43M$5.42M$3.54M$3.03M$4.09M$3.31M$3.18M
Operating income-$2.82M-$5.25M-$27.72M-$4.08M-$3.60M-$7.97M-$10.94M-$13.92M
Interest expense—$0$0$0$0$46,000$161,000$247,000
Income tax—$0$0$0$0$0$0$0
Net income-$3.63M-$5.24M-$27.70M-$4.02M-$3.51M-$7.87M-$10.86M-$13.81M
EBITDA-$2.77M-$5.19M-$27.66M-$4.01M-$3.53M-$7.90M-$10.87M-$13.87M
EPS (basic)-0.21-0.34-2.53—-0.79-2.07-3.16—
EPS (diluted)-0.21-0.34-2.53—-0.79-2.07-3.16—
Weighted avg. shares (diluted)16.91M15.22M10.93M—4.44M3.80M3.44M—
Balance sheet
Cash & equivalents$897,000$779,000$1.80M$7.71M$7.96M$14.72M$21.95M$30.71M
Current assets$1.61M$1.70M$2.45M$8.27M$8.10M$15.10M$22.43M$31.47M
PP&E, net$429,000$486,000$545,000$605,000$681,000$748,000$817,000$886,000
Total assets$8.76M$9.63M$10.75M$16.93M$17.13M$24.48M$32.16M$41.49M
Current liabilities$4.67M$4.45M$3.31M$3.31M$3.52M$7.14M$13.18M$14.22M
Short-term debt———$0$0$0$4.19M$6.35M
Long-term debt——————$4.20M$0
Total debt——————$8.39M$6.35M
Total liabilities$10.59M$10.72M$9.93M$10.26M$10.78M$14.70M$21.03M$22.36M
Shareholders' equity-$1.83M-$1.09M$822,000$6.67M$6.35M$9.78M$11.13M$19.13M
Net debt——————-$13.56M-$24.36M
Shares outstanding16.89M15.98M14.34M4.93M4.44M4.44M3.52M3.38M
Cash flow statement
Operating cash flow-$2.05M-$2.78M-$7.60M-$3.57M-$6.78M-$8.43M-$8.04M-$10.15M
Capital expenditure—$0$0$0$0$0$0$3,000
Free cash flow—-$2.78M-$7.60M-$3.57M-$6.78M-$8.43M-$8.04M-$10.15M
Investing cash flow—$0$0$0$0$0$0-$3,000
Financing cash flow$2.17M$1.75M$1.70M$3.77M$13,000$1.20M-$721,000$17.95M
Depreciation & amortization$57,000$59,000$60,000$65,000$66,000$67,000$68,000$49,000
Stock-based compensation-$54,000-$117,000$226,000$576,000$61,000$1.09M$1.39M$1.33M

Free plan shows the latest 8 periods; Pro shows all 61 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.